malignant pleural effusion
Conditions
Interventions
Pleural cavity perfusion therapy with Endostar:Endostar
Pleural cavity perfusion therapy with Nedaplatin:Nedaplatin
Pleural cavity perfusion therapy with Endostar and Nedaplatin:Endostar and Nedaplatin
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) It was diagnosed as malignant tumor by histopathologic and cytological examination and was clinically diagnosed as malignant pleural effusion, which was above the moderate; 2) Aged between 18 and 75; 3) ECOG scores 0 ~ 2 points; 4) To be expected to survive for more than 2 months; 5) The main organ function is normal; 6) Voluntary enrollment, signed informed consent, compliance with good compliance with follow-up; 7) More than 4 weeks from major surgery.
Exclusion criteria
Exclusion criteria: 1) the metastasis of the central nervous system which was not controlled by the merger was characterized by cranial high pressure; 2) there is a tendency of bleeding, especially in 4 weeks, with obvious gastrointestinal bleeding, or receiving thrombolysis or anticoagulant therapy; 3) the last systemic chemotherapy was < 4 weeks; 4) use other research drugs within 30 days, or participate in other clinical studies at the same time; 5) severe chronic obstructive pulmonary disease and/or respiratory failure, severe intestinal adhesion; 6) pleural effusion or enveloping pleural effusion; 7) patients with poor compliance, or mental illness, cannot control themselves; 8) it is known that this experimental drug and its auxiliary materials are allergic; 9) there are currently uncontrollable serious infections; 10) patients with gestational or lactating women who are not willing to take contraceptive measures (including men); 11) myocardial infarction occurred within 6 months, or at present unstable angina pectoris and cardiac dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression;Quality of life;Safety; | — |
Countries
China
Contacts
Public ContactKong Jinliang
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed